Pharmaceutical Supplier – FDA-Compliant Generic Drug Manufacturer

The contract pertains to the supply of FDA-approved MOXIFLOXACIN HYDROCHLORIDE TABLETS 400 MG, requiring full compliance with federal pharmaceutical standards, current Good Manufacturing Practices (cGMP), and specific military packaging and labeling protocols. The product must be manufactured by a generic drug producer qualified to meet stringent regulatory and defense-specific requirements, ensuring safety, potency, and consistency for use in military healthcare applications. The manufacturer must demonstrate adherence to all applicable federal guidelines and maintain complete traceability and documentation throughout the production and packaging process. The solicitation, issued under the Department of Defense’s Medical Supply Chain Pharma FSA, is classified as a subcontract with a NAICS code of 325412, indicating a focus on pharmaceutical and medicine manufacturing. Responses are due by May 18, 2026, following a posted date of May 11, 2026, with performance to be executed at the FPO 96678 military address. No set-aside provisions are specified, meaning the opportunity is open to all eligible suppliers without preference. The procurement is managed through the DIBBS platform, and all bidders must ensure the product meets exact military specifications for storage, distribution, and deployment in federal healthcare settings.